HDV RNA assays: Performance characteristics, clinical utility, and challenges
Heiner Wedemeyer(Medizinische Hochschule Hannover), Thomas R. Battersby(Gilead Sciences (United States)), Norah A. Terrault(University of California, San Francisco), Harald H. Kessler(Medical University of Graz), Oliver Lenz(Janssen (Belgium)), Saleem Kamili(Centers for Disease Control and Prevention), Veronica Miller(University of California, Berkeley), Tonya Mixson‐Hayden(Centers for Disease Control and Prevention), Christian O. Simon(Roche (Switzerland)), Emmanuel Gordien(Inserm), Gabriel Westman(Uppsala University), Jeffrey S. Glenn(Stanford Medicine), Mitchell Leus(University of California, Berkeley), Hema Kapoor(Medizinische Hochschule Hannover), Pietro Lampertico(University of Milan), Michael M. Thomson(United States Food and Drug Administration), Marc Lütgehetmann(Universität Hamburg)
Cited by 48
Related Papers
Autopsy Findings and Venous Thromboembolism in Patients With COVID-19
|Annals of Internal Medicine|2020|2.4k
Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial
|The Lancet|2014|2.2k
Multiorgan and Renal Tropism of SARS-CoV-2
|New England Journal of Medicine|2020|1.9k
ABT-450/r–Ombitasvir and Dasabuvir with Ribavirin for Hepatitis C with Cirrhosis
|New England Journal of Medicine|2014|877
Tremelimumab in combination with ablation in patients with advanced hepatocellular carcinoma
|Journal of Hepatology|2016|817